Patritumab deruxtecan + Pembrolizumab + Paclitaxel + Carboplatin + Doxorubicin hydrochloride + Epirubicin hydrochloride + Cyclophosphamide + Capecitabine + Olaparib
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Breast Cancer
Trial Timeline
Mar 20, 2025 → Dec 31, 2034
NCT ID
NCT06797635About Patritumab deruxtecan + Pembrolizumab + Paclitaxel + Carboplatin + Doxorubicin hydrochloride + Epirubicin hydrochloride + Cyclophosphamide + Capecitabine + Olaparib
Patritumab deruxtecan + Pembrolizumab + Paclitaxel + Carboplatin + Doxorubicin hydrochloride + Epirubicin hydrochloride + Cyclophosphamide + Capecitabine + Olaparib is a phase 2 stage product being developed by Daiichi Sankyo for Breast Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06797635. Target conditions include Breast Neoplasms, Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06797635 | Phase 2 | Recruiting |
Competing Products
20 competing products in Breast Neoplasms